UK Medical Cannabis Prices Fall 12% as More Brands Enter Market
Average prices for medical cannabis flower products in the UK have fallen by approximately 12% over the past twelve months, driven by increased competition among MHRA-licensed manufacturers and a growing number of import-approved brands from Germany, the Netherlands, and Canada. The price reduction is most pronounced in the mid-tier flower segment, where costs have dropped from an average of £9.50 per gram to £8.40 per gram.
UK Medical Cannabis Market: Prices Drop 12% Amid Growing Competition
Average retail prices for medical cannabis flower in the United Kingdom have fallen by approximately 12% over the twelve months to May 2026, according to pricing data aggregated across major UK pharmacy and specialist dispensary channels. The reduction follows a period of sustained market growth in which several new MHRA-licensed manufacturers have entered the UK formulary, increasing both product variety and pricing competition.
Where the Price Falls Are Happening
The most significant reductions have occurred in the mid-tier flower segment — products with THC content between 18% and 24% that represent the majority of prescriptions. Average prices in this segment have moved from approximately £9.50 per gram to £8.40 per gram over the review period. Premium-tier products (above 24% THC, boutique cultivation) have seen more modest reductions of around 5-7%, while budget-tier options have remained broadly stable.
Cannabis oil and oral spray products have seen smaller price reductions of around 6-8%, partly because the production process for pharmaceutical-grade oil formulations has fewer competitive pressures than dried flower.
Drivers of Competition
Several factors are contributing to the downward price trend. German-origin products have increased their UK market share following regulatory changes that simplified import certification. Canadian and Dutch producers have also expanded UK distribution arrangements with licensed pharmacy networks. Domestically, additional UK cultivation licences issued by the Home Office since 2023 are beginning to yield commercial volumes.
Increased competition at the formulary approval stage — where new brands seek inclusion on clinic prescribing lists — has also created incentives for manufacturers to price competitively.
What This Means for Patients
For patients currently managing monthly cannabis prescription costs of £100 to £400, a 12% reduction in product prices can translate to meaningful savings of £12 to £48 per month. However, price variation between pharmacy suppliers and prescribing platforms remains significant. Patients who have not compared current market pricing recently may find that switching supplier or asking their clinic about alternative formulary options yields further savings. Comparison tools that aggregate current UK medical cannabis pricing can help identify the most cost-effective options for specific product requirements.
